The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.
As of the end of April 2022 we identify the following current VC trends in Europe:
- In 2022, overall Life Sciences funding has reached EUR 3,421m so far
- Top 5 Deals exceed EUR 70m each, largest transaction amounted to EUR 500m in Doctolib (France)
- Two of the Top 5 Deals took place in Germany, Patient21 (EUR 125m) and Ada Health (EUR 106m)
- Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
- The Biotech sector received 43% of the total investment volume
- Oncology still dominates the Biotechnology sector as top indication
Capital Markets Research
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital
Licensing
Life Sciences Venture Capital Monitor – Europe
Monthly Venture capital activities in the European Life Sciences sector
Biotech Venture Capital Monitor – USAMonthly Venture capital activities in the US Life Sciences sector
Life Sciences Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Other Research
Life Sciences IPO ReportRecent IPO trends in the Life Sciences sector
Biotech Public Equity MonitorRecent valuations of listed European Life Sciences companies
MedTech & Diagnostics Public Equity MonitorRecent valuations of listed MedTech companies
Life Sciences SPAC MonitorPerformance overview of merged Life Sciences SPACs
NEWS
German CVC as most active corporate investor in the European life sciences sector
With 44 deals, the corporate venture arm of Boehringer Ingelheim was the most active corporate investor in the European life science market in the last five years. The only other investor having reached the top
FCF Life Sciences Venture Capital Monitor – Europe 04/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life
Overview of top VC investors in European life sciences markets
It is no surprise that the top 5 European investors have shown significantly higher activities than US investors in Europe from 2017 to 2021. Nevertheless, US investors such as SOSV, Epidarex Capital, OrbiMed, and RA
FCF Biotech Venture Capital Monitor – USA 03/2022 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 03/2022”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
Significant cool-down of BioTech IPOs in Europe and the US
The capital raised in BioTech IPOs declined heavily in Europe and the US. For Q4’21 – Q1’22, the amount of raised capital declined by 73 percent compared to Q4’20 – Q1’21 (from EUR 5,941m to
